AxoGen (NASDAQ:AXGN) Stock Price Expected to Rise, Truist Financial Analyst Says

Key Points

• Truist Financial raised AxoGen’s price target from $53 to $60 and maintained a “buy” rating, implying 19.69% upside from the previous close.
• AxoGen reported quarterly earnings of $0.21 per share and revenue of $75.83 million, exceeding analyst expectations; management also raised full-year 2026 revenue guidance to at least $290 million.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $56.91, although the company continues to post negative net margins and return on equity.

AxoGen (NASDAQ:AXGN - Get Free Report) had its price target hoisted by Truist Financial from $53.00 to $60.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the medical equipment provider's stock. Truist Financial's target price indicates a potential upside of 19.69% from the company's previous close.

AXGN has been the subject of a number of other research reports. Citizens Jmp raised their price objective on shares of AxoGen from $50.00 to $55.00 and gave the company a "market outperform" rating in a report on Thursday, July 30th. Barclays reissued an "overweight" rating and issued a $60.00 price objective on shares of AxoGen in a research note on Thursday. Wells Fargo & Company raised their target price on AxoGen from $48.00 to $56.00 and gave the stock an "overweight" rating in a research report on Thursday. Raymond James Financial reaffirmed an "outperform" rating and set a $57.00 target price on shares of AxoGen in a report on Thursday. Finally, Wall Street Zen lowered AxoGen from a "buy" rating to a "hold" rating in a research report on Saturday, September 26th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $56.91.

AxoGen Price Performance

NASDAQ AXGN traded up $0.88 during trading on Thursday, hitting $50.13. 212,528 shares of the company's stock were exchanged, compared to its average volume of 1,191,701. The company has a market cap of $2.69 billion, a PE ratio of -73.09 and a beta of 1.17. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. The stock's 50 day moving average price is $42.78 and its two-hundred day moving average price is $39.28. AxoGen has a fifty-two week low of $21.68 and a fifty-two week high of $52.91.

AxoGen (NASDAQ:AXGN - Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.18 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Research analysts expect that AxoGen will post -0.44 EPS for the current year.

Insider Activity at AxoGen

In other AxoGen news, Director Amy Wendell sold 13,353 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the completion of the transaction, the director owned 107,976 shares in the company, valued at $5,228,197.92. This represents a 11.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph A. Tyndall sold 3,500 shares of AxoGen stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the sale, the director directly owned 10,650 shares of the company's stock, valued at approximately $529,305. This trade represents a 24.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,503 shares of company stock worth $4,656,947 over the last three months. 2.44% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Nykredit A S bought a new position in shares of AxoGen during the 2nd quarter valued at $30,000. KBC Group NV bought a new position in shares of AxoGen during the first quarter valued at about $41,000. Sterling Capital Management LLC increased its holdings in shares of AxoGen by 858.9% in the third quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider's stock worth $74,000 after buying an additional 1,589 shares during the period. State of Alaska Department of Revenue lifted its stake in shares of AxoGen by 16.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider's stock valued at $118,000 after acquiring an additional 409 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in AxoGen during the 2nd quarter valued at about $203,000. 80.29% of the stock is owned by institutional investors.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. AxoGen reported adjusted earnings of $0.21 per share, versus the $0.13–$0.14 consensus range, while revenue increased to $75.83 million from an expected $73.18 million. Earnings also improved from $0.12 per share a year earlier. AxoGen Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management raised 2026 revenue guidance. AxoGen now expects full-year revenue of at least $290 million, representing minimum growth of 29%. The higher outlook signals continued demand for its peripheral nerve repair products and was a key catalyst for investor enthusiasm. AxoGen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright raised its price target to $56 from $53 and maintained a Buy rating. The revised target implies additional upside from the reported $49.25 reference price and reinforces the improving analyst view of AXGN’s growth prospects. HC Wainwright stock recommendations
• Positive Sentiment: Options activity reflected strong speculative interest. Investors purchased 9,886 call options, compared with average daily call volume of about 900, suggesting increased bullish positioning after the earnings release.
• Neutral Sentiment: Despite the earnings beat, AxoGen continues to report a negative net margin and negative return on equity. Its elevated valuation following the rally could also limit further gains unless revenue growth and profitability continue to improve. Does AxoGen Have More Upside?

About AxoGen

AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.